Emergency Practice Innovation Centre, St Vincent's Hospital Melbourne and Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Victoria, Australia.
Aust N Z J Public Health. 2010 Apr;34(2):172-8. doi: 10.1111/j.1753-6405.2010.00503.x.
To assess lifestyle and pharmacological interventions aiming to delay type 2 diabetes mellitus (T2DM) in prediabetes.
We searched the Cochrane Register of Controlled Trials, MEDLINE, EMBASE, CINAHL, PsycINFO, Web of Science, BIOSIS and LILACS databases, examined reference lists and contacted authors. We included randomised controlled trials (RCTs) on both lifestyle and medication interventions in prediabetes. These studies were at least 12 month duration and aimed to delay T2DM.
Four studies investigating lifestyle and medication with a total of 5,196 participants were identified. There was a high risk of bias in the studies and the interventions utilised varied considerably; thus, meta-analysis was not undertaken. The comparison between lifestyle and medication interventions was largely dependent on the intensity of the lifestyle program while we could not adequately assess their effects on cardiovascular morbidity. Adverse events with metformin and acarbose were common.
There is substantial evidence that intensive lifestyle programs and medications delay T2DM in impaired glucose tolerance though it remains unclear which is more effective.
Both interventions seem to be able to delay T2DM. However, both have issues with adherence and side effects and more RCTs are required.
评估旨在延缓糖尿病前期 2 型糖尿病(T2DM)的生活方式和药物干预措施。
我们检索了 Cochrane 对照试验注册库、MEDLINE、EMBASE、CINAHL、PsycINFO、Web of Science、BIOSIS 和 LILACS 数据库,查阅了参考文献列表,并联系了作者。我们纳入了糖尿病前期的生活方式和药物干预的随机对照试验(RCT)。这些研究的持续时间至少为 12 个月,旨在延缓 T2DM 的发生。
确定了四项研究,共涉及 5196 名参与者,分别对生活方式和药物干预进行了调查。研究存在较高的偏倚风险,所采用的干预措施差异很大;因此,未进行荟萃分析。生活方式和药物干预之间的比较在很大程度上取决于生活方式计划的强度,而我们无法充分评估它们对心血管发病率的影响。二甲双胍和阿卡波糖的不良反应很常见。
有大量证据表明,强化生活方式计划和药物治疗可延缓糖耐量受损患者的 T2DM,但哪种方法更有效仍不清楚。
这两种干预措施似乎都能延缓 T2DM 的发生。然而,两种方法都存在依从性和副作用的问题,需要更多的 RCT 来验证。